The phrase "abnormalities of liver function" is correct and usable in written English.
It can be used in medical contexts to describe irregularities or issues related to how the liver is functioning.
Example: "The patient was diagnosed with abnormalities of liver function, which required further testing and monitoring."
Alternatives: "liver function irregularities" or "liver function anomalies".
Abnormalities of liver function tests (LFT) are sometimes taken as evidence of a less than optimal result after repair of a biliary injury.
Mucositis, fatigue, rashes and abnormalities of liver function were also rarely reported.
Patients with systemic sclerosis may develop mild abnormalities of liver function tests.
Abnormalities of liver function occur frequently in patients with rheumatic conditions.
Isolated abnormalities of liver function tests (e.g., increased bilirubin and/or liver enzymes) without evidence of hepatitis or hepatosis.
Suggested dose modifications are highlighted in Table 3. Abnormalities of liver function tests (LFTs) have been observed in patients treated with MKI therapy.
The main anticipated serious adverse event (SAE) for riluzole was serious abnormality of liver function tests defined as ALT >5× the upper limit of normal.
The abnormality of liver function tests may be secondary to serious disease elsewhere requiring treatment, such as malignancy where its early detection may improve the prognosis.
Clinically, no significant abnormalities were seen and no significant decreases of liver function or liver function abnormalities were seen in this particular group of patients.
The prevalence of liver function abnormalities ranges from 20 to 80%% [3, 4], and a few reports have described severe consequences of the liver involvement [5].
The research firm said Thelin possesses "four key advantages" over Tracleer, made by Actelion: once versus twice daily dosing, a lower incidence of liver function abnormalities, a superior combination profile with Pfizer (nyse: PFE) drug Revatio, and the potential for approval in Class II-IV pulmonary arterial hypertension (PAH).
